Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple Myeloma
The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Lenalidomide is a structural analogue of thalidomide with similar but more potent biologic activity. This phase 3, placebo-controlled trial investigated the efficacy of lenalidomide plus dexamethasone in the treatment of relapsed or refractory multiple myeloma. METHODS: Of 351 patients who had received at least one previous antimyeloma therapy, 176 were randomly assigned to receive 25 mg of oral lenalidomide and 175 to receive placebo on days 1 to 21 of a 28-day cycle. In addition, all patients received 40 mg of oral dexamethasone on days 1 to 4, 9 to 12, and 17 to 20 for the first four cycles and subsequently, after the fourth cycle, only on days 1 to 4. Patients continued in the study until the occurrence of disease progression or unacceptable toxic effects. The primary end point was time to progression. RESULTS: The time to progression was significantly longer in the patients who received lenalidomide plus dexamethasone (lenalidomide group) than in those who received placebo plus dexamethasone (placebo group) (median, 11.3 months vs. 4.7 months; P<0.001). A complete or partial response occurred in 106 patients in the lenalidomide group (60.2%) and in 42 patients in the placebo group (24.0%, P<0.001), with a complete response in 15.9% and 3.4% of patients, respectively (P<0.001). Overall survival was significantly improved in the lenalidomide group (hazard ratio for death, 0.66; P=0.03). Grade 3 or 4 adverse events that occurred in more than 10% of patients in the lenalidomide group were neutropenia (29.5%, vs. 2.3% in the placebo group), thrombocytopenia (11.4% vs. 5.7%), and venous thromboembolism (11.4% vs. 4.6%). CONCLUSIONS: Lenalidomide plus dexamethasone is more effective than high-dose dexamethasone alone in relapsed or refractory multiple myeloma. (ClinicalTrials.gov number, NCT00424047 [ClinicalTrials.gov].).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Daratumumab with lenalidomide and dexamethasone was associated with clinically manageable adverse events that were consistent with the known toxic effects of lenalidomide and dexamethasone 27,28,30,31 and of daratumumab.9,10”
From Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma. (2016) · cites this paper as [31]
In the citing paper
“(iv) they are already a therapeutic reality.[56][57][58][59][60][61][62][63][64][65][66][67]”
From Chasing molecular glue degraders: screening approaches (2022) · cites this paper as [57]
In the citing paper
“A randomized study comparing lenalidomide and dexamethasone to melphalan, thalidomide and prednisone in newly diagnosed patients demonstrated superior 4-year OS (59% versus 51%; HR 0.78, p=0.02) and led to FDA approval in 201527.”
From Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide (2021) · cites this paper as [27]
In the citing paper
“For older patients and/or those unfit for autologous transplantation, the preferred induction approach remains lenalidomide in combination with dexamethasone with or without daratumumab, regimens that are effective and well tolerated in this patient population27,29.”
From Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide (2021) · cites this paper as [27]
In the citing paper
“Thalidomide analogues often lead to peripheral blood cytopenias, most commonly neutropenia (28% grade 3/4) and thrombocytopenia (8% grade 3/4)27.”
From Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide (2021) · cites this paper as [27]
Citations
Cites
Antitumor Activity of Thalidomide in Refractory Multiple Myeloma
Singhal, S., Mehta, J., Desikan, R., Ayers, D., Roberson, P., Eddlemon, P., Munshi, N., Anaissie, E., Wilson, C., Dhodapkar, M., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199911183412102 · Cited by 2,575
Self-citationBladÉ, J., Samson, D., Reece, D., Apperley, J., BJÖrkstrand, B., Gahrton, G., Gertz, M., Giralt, S., Jagannath, S., Vesole, D., et al. (1998) · British Journal of Haematology · doi:10.1046/j.1365-2141.1998.00930.x · Cited by 1,519
Cancer incidence and mortality in Europe, 2004
Boyle, P., & Ferlay, J. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi098 · Cited by 1,217
Hideshima, T., Chauhan, D., Shima, Y., Raje, N., Davies, F. E., Tai, Y.-T., Treon, S. P., Lin, B., Schlossman, R. L., Richardson, P., et al. (2000) · Blood · doi:10.1182/blood.v96.9.2943 · Cited by 875
Richardson, P. G., Schlossman, R. L., Weller, E., Hideshima, T., Mitsiades, C., Davies, F., LeBlanc, R., Catley, L. P., Doss, D., Kelly, K., et al. (2002) · Blood · doi:10.1182/blood-2002-03-0996 · Cited by 804
Self-citationRichardson, P. G., Blood, E., Mitsiades, C. S., Jagannath, S., Zeldenrust, S. R., Alsina, M., Schlossman, R. L., Rajkumar, S. V., Desikan, K. R., Hideshima, T., et al. (2006) · Blood · doi:10.1182/blood-2006-04-015909 · Cited by 523
Self-citationCombination Therapy With Thalidomide Plus Dexamethasone for Newly Diagnosed Myeloma
Rajkumar, S. V., Hayman, S., Gertz, M. A., Dispenzieri, A., Lacy, M. Q., Greipp, P. R., Geyer, S., Iturria, N., Fonseca, R., Lust, J. A., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.02.116 · Cited by 512
Molecular mechanisms of novel therapeutic approaches for multiple myeloma
Hideshima, T., & Anderson, K. C. (2002) · Nature Reviews Cancer · doi:10.1038/nrc952 · Cited by 425
Thalidomide and dexamethasone combination for refractory multiple myeloma
Dimopoulos, M. A., Zervas, K., Kouvatseas, G., Galani, E., Grigoraki, V., Kiamouris, C., Vervessou, E., Samantas, E., Papadimitriou, C., Economou, O., et al. (2001) · Annals of Oncology · doi:10.1023/a:1011132808904 · Cited by 283
Self-citationGarcía-Sanz, R., González-Porras, J. R., Hernández, J. M., Polo-Zarzuela, M., Sureda, A., Barrenetxea, C., Palomera, L., López, R., Grande-García, C., Alegre, A., et al. (2004) · Leukemia · doi:10.1038/sj.leu.2403322 · Cited by 159
Self-citation
Cited by
Items 901–1,000 of 1,000
Guglielmelli, T., Petrucci, M. T., Saglio, G. N., & Palumbo, A. (2010) · British Journal of Haematology · doi:10.1111/j.1365-2141.2010.08416.x · Cited by 8
“Lenalidomide remains active in relapsed and refractory MM patients previously exposed to thalidomide (Dimopoulos et al, 2007; Weber et al, 2007; Wang et al, 2008).”
BackgroundJulio, A. R., Shikwana, F., Truong, C. C., Burton, N. R., Dominguez, E. R., Turmon, A. C., Cao, J. X., & Backus, K. M. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.10.30.564067 · Cited by 10
Breathing New Life into Old Drugs: Indication Discovery by Systems Directed Therapy
Bundscherer, A., & Hafner, C. M. (2010) · Springer eBooks · doi:10.1007/978-90-481-9531-2_24 · Cited by 7
Novel Drugs in Myeloma: Harnessing Tumour Biology to Treat Myeloma
Boyd, K. D., Davies, F. E., & Morgan, G. J. (2011) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-540-85772-3_8 · Cited by 7
Molecular Glue Degraders: From Serendipity to Hunting and Design
Nieto‐Barrado, L., Domostegui, A., & Mayor‐Ruiz, C. (2022) · Wiley eBooks · doi:10.1002/9783527836208.ch6 · Cited by 10
Peripheral T-cell lymphoma: new therapeutic strategies.
Petrich, A. M., & Rosen, S. T. (2013) · PubMed · Cited by 8
Treatment of patients with multiple myeloma over 65 yr: more tolerability or better response?
Tarkun, P., Atalay, F., Ateşoğlu, E. B., Mehtap, Ö., Şimşek, M., Terzi, E., Gedük, A., Balli, F., Batman, A., Baydemır, C., et al. (2014) · European Journal Of Haematology · doi:10.1111/ejh.12448 · Cited by 7
Tosi, P., Gamberi, B., Castagnari, B., Molinari, A. L., Savini, P., Ceccolini, M., Tani, M., Merli, A., Imola, M., Mianulli, A. M., et al. (2013) · Mediterranean Journal of Hematology and Infectious Diseases · doi:10.4084/mjhid.2013.037 · Cited by 8
“patients clinical conditions Median treatment duration was 16 months (1-22), therapy was”
BackgroundBaertsch, M., Schlenzka, J., Mai, E. K., Merz, M., Hillengaß, J., Raab, M. S., Hose, D., Wuchter, P., Ho, A. D., Jauch, A. S., et al. (2016) · BMC Cancer · doi:10.1186/s12885-016-2321-2 · Cited by 7
“After completion of the 4 cycle, dexamethasone was limited to days 1–4 [8, 9].”
BackgroundOortgiesen, B. E., van Roon, E. N., Joosten, P., Kibbelaar, R. E., Storm, H., Hovenga, S., van Rees, B. P., Woolthuis, G., Veeger, N. J. G. M., Waal, E. G. M. D., et al. (2017) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-017-2227-1 · Cited by 7
Multiple myeloma and chemical maxillary osteonecrosis. Can both occur simultaneously?
Junquera, S., Álvarez-Yagüe, E., Junquera, L. M., Ugalde, R., & Rúa, L. (2019) · Journal of Stomatology Oral and Maxillofacial Surgery · doi:10.1016/j.jormas.2019.12.002 · Cited by 7
Sugi, T., Mita, M., Yasu, T., Ohara, S., Uchida, T., Inoue, M., & Hagihara, M. (2021) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.13433 · Cited by 7
Weiß, D., Knight, R., Zhou, S. Y., Palmisano, M., & Chen, N. (2015) · Clinical Drug Investigation · doi:10.1007/s40261-015-0299-1 · Cited by 7
“Lenalidomide, an oral immunomodulatory drug and analog of thalidomide [1, 2], is approved for the treatment of multiple myeloma (MM) in combination with dexamethasone [3, 4]; myelodysplastic syndromes associated with”
BackgroundSelf-citationDmoszyńska, A., Walter‐Croneck, A., Usnarska‐Zubkiewicz, L., Stella-Holowiecka, B. M., Walewski, J. A., Charliński, G., Wiktor-Jędrzejczak, W., Wiater, E., Lech‐Marańda, E., Mańko, J., et al. (2013) · Acta Haematologica Polonica · doi:10.1016/j.achaem.2013.02.006 · Cited by 7
Mateos, M., Prósper, F., Martín, J., Ocio, E. M., Oriol, A., Motlló, C., Michot, J., Jarque, I., Iglesias, R., Solé, M., et al. (2022) · Cancer Medicine · doi:10.1002/cam4.5250 · Cited by 8
Khalafallah, A. A., Woodgate, M., Koshy, K., & Patrick, A. (2013) · BMJ Case Reports · doi:10.1136/bcr-2012-007625 · Cited by 7
Olivier, P., Teisseyre, A.-C., & Montastruc, J. (2013) · Medical Oncology · doi:10.1007/s12032-013-0733-2 · Cited by 7
Novel agents in myeloma: An exciting saga
Mark, T. M., Niesvizky, R., & Coleman, M. (2008) · Cancer · doi:10.1002/cncr.24040 · Cited by 7
“tested lenalidomide and dexamethasone against dexamethasone in previously treated patients.(23,24) Combined dexa-”
BackgroundFatal ischemic stroke in a patient receiving lenalidomide for multiple myeloma
Tannemaat, M. R., Vries, E. P., Molendijk, W. J., & Haan, J. (2011) · Clinical Neurology and Neurosurgery · doi:10.1016/j.clineuro.2011.01.003 · Cited by 7
Risk Stratification in the Era of Novel Therapies
Miguel, J. F. S., Mateos, M., & Gutierrez, N. C. (2009) · The Cancer Journal · doi:10.1097/ppo.0b013e3181c51efa · Cited by 7
Self-citationUpdate on the pharmacotherapy for myelodysplastic syndromes
Duong, V. H., Komrokji, R. S., & List, A. F. (2014) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2014.937705 · Cited by 8
“While deep venous thrombosis is a well-known adverse event associated with the use of lenalidomide with dexamethasone or traditional cytotoxic agents in multiple myeloma [68-71], it was reported in only 3% of MDS patients [54,63-65].”
BackgroundHoyle, M., Rogers, G., Garside, R., Moxham, T., & Stein, K. (2008) · Cited by 12
Dhakal, B., Narra, R. K., Giri, S., Szabó, A., Smunt, T. L., Ghose, S., Pathak, L. K., Aryal, M. R., Hamadani, M., Chhabra, S., et al. (2020) · Cancer · doi:10.1002/cncr.32831 · Cited by 7
Old and new generation immunomodulatory drugs in multiple myeloma
Derudas, D., Capraro, F., Martinelli, G., & Cerchione, C. (2021) · Panminerva Medica · doi:10.23736/s0031-0808.20.04125-7 · Cited by 8
Ding, K., Yu, H., Shao, Y., Li, L., Wang, C.-M., Song, J., Li, L., & Fu, R. (2020) · Cancer Management and Research · doi:10.2147/cmar.s261887 · Cited by 8
Calamia, M., McBride, A., & Abraham, I. L. (2021) · Journal of Medical Economics · doi:10.1080/13696998.2021.2007704 · Cited by 7
Major, A., Jakubowiak, A. J., & Derman, B. A. (2022) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2022.07.002 · Cited by 7
Lenalidomide before and after Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma
Tuchman, S. A., Chao, N. J. A., & Gasparetto, C. (2012) · Advances in Hematology · doi:10.1155/2012/712613 · Cited by 7
“…5 April 2012 Academic Editor: Antonio Palumbo Copyright © 2012 S. A. Tuchman et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.”
Cost–effectiveness of lenalidomide in multiple myeloma
Schey, S., & Higginson, I. J. (2010) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1586/erp.10.19 · Cited by 7
Iida, S., Nagai, H., Kinoshita, G., Miyoshi, M., Robbins, M. D. H., Pandya, D., Bleickardt, E. W., & Chou, T. (2016) · International Journal of Hematology · doi:10.1007/s12185-016-2138-4 · Cited by 7
Hinduja, A., Limaye, K. S., Ravilla, R., Sasapu, A., Papanikolaou, X. D., Wei, L., Torbey, M., & Waheed, S. (2016) · PLoS ONE · doi:10.1371/journal.pone.0166627 · Cited by 7
Aceituno, S., Gozalbo, I., Appierto, M., & Lizán, L. (2018) · Medwave · doi:10.5867/medwave.2018.03.7220 · Cited by 7
Analysis of risk factors for lenalidomide-associated skin rash in patients with multiple myeloma
Sugi, T., Nishigami, Y., Hirohisa, S., Hanai, H., Keisuke, T., Mita, M., Ohara, S., Ide, S., Uchida, T., Inoue, M., et al. (2021) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2021.1876867 · Cited by 8
Current and emerging triplet combination therapies for relapsed and refractory multiple myeloma
Pantani, L., Brioli, A., Tacchetti, P., Zannetti, B. A., Mancuso, K., Rocchi, S., Martello, M., Rizzello, I., Terragna, C., Zamagni, E., et al. (2015) · Expert Review of Hematology · doi:10.1586/17474086.2016.1127754 · Cited by 7
“methasone alone in terms of ORR and median PFS [30,31].”
BackgroundGuglieri-López, B., Pérez‐Pitarch, A., Martínez‐Gómez, M. A., Porta-Oltra, B., Martí, M. C., & Merino‐Sanjuán, M. (2016) · SLAS TECHNOLOGY · doi:10.1177/2211068216636570 · Cited by 7
“The steps followed for the extraction of LND were (1) cartridge conditioning with methanol (2 mL), (2) solidphase equilibration with 0.”
MethodYuan, L., Ji, W., Dwyer, B. G., Lu, J., Bian, J. T., Colombo, G. M., Martinez, M. J., Fernández, D., Phillips, N. A., Tang, M. T., et al. (2025) · Cancer Discovery · doi:10.1158/2159-8290.cd-25-0271 · Cited by 9
“Molecular glues, small molecules that induce cooperative protein–protein binding events (7–9), have transformed the treatment of hematologic malignancies (10, 11) but have not yet been approved for common solid tumors despite early promise (12).”
Simplifying Access to Targeted Protein Degraders via Nickel Electrocatalytic Cross‐Coupling
Neigenfind, P., Massaro, L., Péter, Á., Degnan, A. P., Emmanuel, M. A., Oderinde, M. S., He, C., Peters, D., Ewing, T. E., Kawamata, Y., et al. (2024) · Angewandte Chemie · doi:10.1002/ange.202319856 · Cited by 6
Using protein turnover assay to explore the drug mechanism of Carfilzomib
Tao, Y., Ding, X., Jia, C., Wang, C., & Li, C. (2024) · Acta Biochimica et Biophysica Sinica · doi:10.3724/abbs.2024104 · Cited by 6
Design and synthetic approaches to thalidomide based small molecule degraders
Kumar, A., Kumar, G., Kalia, N., & Sahoo, P. R. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.117700 · Cited by 7
Systematic Review and Network Meta-Analysis of Treatment Outcomes for Multiple Myeloma
Armoiry, X., Tsertsvadze, A., Connock, M. J., Meléndez‐Torres, G. J., & Clarke, A. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.73.1828 · Cited by 6
on behalf of the Japan Study Group for Cell Therapy and Transplantation (JSCT), Fuchida, S., Sunami, K., Matsumoto, M., Okumura, H., Murayama, T., Miyamoto, T., Otsuka, E., Fujishima, N., Izumi, T., et al. (2018) · International Journal of Hematology · doi:10.1007/s12185-018-2543-y · Cited by 6
Validation of Risk-Adapted Venous Thromboembolism Prediction in Multiple Myeloma Patients
Barrett, A., Quinn, J., Lavin, M., Thornton, P. D., O’Donnell, J. S., Murphy, P. T., & Glavey, S. V. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10163536 · Cited by 6
“The IMiD-related VTE risk is also influenced by combination with high-dose glucocorticoids, with several studies demonstrating the incidence of VTE to be almost three times higher in lenalidomide and dexamethasone (RD)-treated patients than in those receiving dexamethasone alone [3,4].”
BackgroundExpedited Aminoglutarimide C–N Cross-Coupling Enabled by High-Throughput Experimentation
Gu, J. W., Oderinde, M. S., Li, H., ROBERTS, F. E., Ganley, J. M., & Palkowitz, M. D. (2024) · The Journal of Organic Chemistry · doi:10.1021/acs.joc.4c02536 · Cited by 6
Allogeneic Stem Cell Transplantation and Targeted Immunotherapy for Multiple Myeloma
Danylesko, I., Shimoni, A., & Nagler, A. (2013) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2013.05.021 · Cited by 6
Optimal management of elderly patients with myeloma
Cerrato, C., Mina, R., & Palumbo, A. P. (2013) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.2014.856269 · Cited by 6
Conflicts of Interest, Authorship, and Disclosures in Industry-Related Scientific Publications–2
Fonseca, R., Richardson, P. G. G., Giralt, S., Lonial, S., Rajkumar, S. V., Stewart, A. K., Bensinger, W., Somlo, G., Vescio, R., Mikhael, J., et al. (2010) · Mayo Clinic Proceedings · doi:10.4065/mcp.2009.0559 · Cited by 6
Rushworth, G. F., Leslie, S. J., Forsyth, P. D., & Vincent, C. (2012) · Therapeutic Advances in Drug Safety · doi:10.1177/2042098611433773 · Cited by 6
“com Lenalidomide in multiple myeloma The licence for the use of lenalidomide and dexamethasone for relapsed or refractory multiple myeloma was given initially based on the results of two parallel randomized, double-blind, placebo-controlled phase III studies [Dimopoulos et al. 2007; Weber et al. 2007].”
MethodResultInfluentialChoosing treatment options for patients with relapsed/refractory multiple myeloma
Castelli, R., Orofino, N., Losurdo, A., Gualtierotti, R., & Cugno, M. (2013) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.2014.863153 · Cited by 6
Maintenance therapy in newly diagnosed multiple myeloma: current recommendations
Brioli, A., Tacchetti, P., Zamagni, E., & Cavo, M. (2014) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.2014.884930 · Cited by 7
“However, despite grade 3–4 neutropenia being reported in about 25% of the patients, grade 3–4 febrile neutropenia is rare, occurring in less than 10% of cases [36,50].”
BackgroundTotani, H., Ri, M., Kato, C., Nakashima, T., Suzuki, N., Hagiwara, S., Kanamori, T., Murakami, S., Masuda, A., Kinoshita, S., et al. (2015) · International Journal of Hematology · doi:10.1007/s12185-015-1925-7 · Cited by 6
“Novel agents, including proteasome inhibitors (PIs) [1, 2] and immunomodulatory drugs (IMiDs) [3, 4], have improved patient responses in the treatment of this incurable disease as well as the outcomes of patients with relapsed or refractory (RR) MM.”
BackgroundSupportive Therapies in Multiple Myeloma
Gleason, C. L., Nooka, A. K., & Lonial, S. (2009) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2009.0064 · Cited by 6
Knauf, W. U., Aldaoud, A., Losem, C. J., Mittermueller, J., Neise, M., Niemeier, B., Harde, J., Trarbach, T., & Potthoff, K. (2018) · Leukemia Research · doi:10.1016/j.leukres.2018.03.008 · Cited by 6
Maisnar, V., Štefániková, Z., Spicka, I., Pour, L., Minařík, J., Flochova, M., Radocha, J., Gregora, E., Stecova, N., Jelínek, T., et al. (2019) · Neoplasma · doi:10.4149/neo_2018_180824n644 · Cited by 7
“Previous studies have shown the important role of LEN/DEX as the therapy in patients with relapsed multiple myeloma [16][18][20].”
ResultFerreira, L. M., Cerezer, J. L., & Gehrcke, M. (2020) · Hematology Transfusion and Cell Therapy · doi:10.1016/j.htct.2020.05.009 · Cited by 6
Mikulski, D., Robak, P. J., Ryżewska, W., Stańczak, K., Kościelny, K., Góra‐Tybor, J., & Robak, T. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11195908 · Cited by 6
“treated with at least one line of therapy [6,7].”
BackgroundDmoszyńska, A., Walter‐Croneck, A., Mańko, J., Usnarska‐Zubkiewicz, L., Stella-Holowiecka, B. M., Walewski, J. A., Charliński, G., Wiktor-Jędrzejczak, W., Wiater, E., Lech‐Marańda, E., et al. (2012) · Acta Haematologica Polonica · doi:10.1016/s0001-5814(12)31003-7 · Cited by 6
Musuraca, G., Fattori, P. P., Ceccolini, M., Cangini, D., Giannini, M. B., Ronconi, S., Matteucci, F., Asioli, S., & Amadori, D. (2010) · American Journal of Hematology · doi:10.1002/ajh.21869 · Cited by 6
Wong, R., Golombick, T., DIAMOND, T. H., Manoharan, A., & Ramakrishna, R. (2013) · Journal of Hematological Malignancies · doi:10.5430/jhm.v3n2p1 · Cited by 7
“ISSN 1925-4024 E-ISSN 1925-4032 6 About one third of patients with relapsed or refractory myeloma respond to thalidomide-containing treatment, and this response rate improves to 60% with a lenalidomide-containing regimen ([23]).”
BackgroundYoshida, T., Ri, M., Fujinami, H., Oshima, Y., Tachita, T., Marumo, Y., Sasaki, H., Kinoshita, S., Totani, H., Narita, T., et al. (2019) · International Journal of Hematology · doi:10.1007/s12185-019-02669-z · Cited by 6
Salomon‐Perzyński, A., Bluszcz, A., Krzywdzińska, A., Spyra-Górny, Z., Jakacka, N., Barankiewicz, J., Borg, K., Solarska, I., Szpila, T., Puła, B., et al. (2020) · Polskie Archiwum Medycyny Wewnętrznej · doi:10.20452/pamw.15316 · Cited by 9
Lee, H. S., Kım, K., Lee, J., Yoon, S., Bang, S., Kim, J. S., Eom, H., Yoon, D. H., Lee, Y., Shin, H., et al. (2020) · International Journal of Hematology · doi:10.1007/s12185-020-02988-6 · Cited by 6
Miki, H., Ozaki, S., Nakamura, S., Oda, A., Amou, H., Ikegame, A., Watanabe, K., Hiasa, M., Cui, Q., Harada, T., et al. (2011) · British Journal of Haematology · doi:10.1111/j.1365-2141.2011.08844.x · Cited by 6
“In recent years, new classes of drugs, such as thalidomide (Singhal et al, 1999), lenalidomide (Dimopoulos et al, 2007; Weber et al, 2007) and bortezomib (Richardson et al, 2005), have been introduced into clinical practice showing better quality of responses.”
BackgroundTreatment of relapsed and refractory myeloma
Kaufman, J. L., Gleason, C. L., & Lonial, S. (2009) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-009-0014-5 · Cited by 6
Majer, I. M., van de Wetering, G., Polányi, Z., Krishna, A., Gray, E., & Roy, A. N. (2016) · Applied Health Economics and Health Policy · doi:10.1007/s40258-016-0271-0 · Cited by 7
“DEX was obtained used the pivotal MM-009 (n = 330, NCT00056160) [19] and MM-010 (n = 290, NCT00424047) [19] trials.”
MethodNouvelles thérapies du myélome
Azaïs, I., Brault, R., & Debiais, F. (2010) · Revue du Rhumatisme · doi:10.1016/j.rhum.2009.09.008 · Cited by 7
Diagnosis and Treatment of Multiple Myeloma
Rajkumar, S. V., & Kyle, R. A. (2012) · Springer eBooks · doi:10.1007/978-1-4614-3764-2_33 · Cited by 6
Urata, C., Yoshimura, M., Itamura, H., Hisatomi, T., Kubota, Y., Fukushima, N., Sueoka, E., & Kimura, S. H. (2011) · International Journal of Hematology · doi:10.1007/s12185-011-0903-y · Cited by 6
“4% in phase III studies (MM-009 and MM-010) of lenalidomide plus DEX for relapsed or refractory MM [4, 5].”
Multiple myeloma and immunomodulation: regulating the regulatory cells
Kasyapa, C. S., Sher, T., & Chanan-Khan, A. A. (2012) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2012.670233 · Cited by 6
“In particular, the combination of dexamethasone, an immunosuppressant, and lenalidomide resulted in an impressive and long-lasting remission in patients with relapsed and/ or refractory MM [9].”
BackgroundNew treatments in multiple myeloma: beyond optimal treatment
Harousseau, J. (2008) · Annals of Oncology · doi:10.1093/annonc/mdn314 · Cited by 6
“CR rate (15% versus 1–3%), PFS (11 months versus 5 months) and OS [12, 13].”
BackgroundSelf-citationIncorporating Novel Agents in the Management of Elderly Myeloma Patients
Guglielmelli, T., & Palumbo, A. P. (2013) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-013-0177-y · Cited by 6
“The MM09 and MM010 trials showed the superiority of RD (lenalidomide, 25 mg oral on days 1–21 every 28 days) [41, 42] versus dexamethasone alone in terms of overall response rate (60 % vs 20–24%), TTP (11 vs 4.”
BackgroundResultContinuous treatment in multiple myeloma: The future?
Broek, I. V., & Jacobs, P. (2013) · Transfusion and Apheresis Science · doi:10.1016/j.transci.2013.07.017 · Cited by 6
“icity) and more potent than its parent drug Thalidomide [10,11].”
BackgroundMultiple Myeloma: The Role of Angiogenesis in Disease Progression
Ria, R. (2013) · Journal of Bone Marrow Research · doi:10.4172/2329-8820.1000117 · Cited by 5
Evolving Strategies in the Initial Treatment of Multiple Myeloma
Rosenbaum, C. A., Jasielec, J. K., Laubach, J. P., Prada, C. P., Richardson, P. G. G., & Jakubowiak, A. J. (2013) · Seminars in Oncology · doi:10.1053/j.seminoncol.2013.08.002 · Cited by 5
Practical guidance for new multiple myeloma treatment regimens: A nursing perspective
Epstein, M., & Morrison, C. (2022) · Seminars in Oncology · doi:10.1053/j.seminoncol.2022.01.010 · Cited by 5
Khan, S., Bergstrom, D. J., Côté, J. A., Kotb, R. R., LeBlanc, R., Louzada, M., Mian, H. S., Othman, I., Colasurdo, G., & Visram, A. (2024) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2024.10.012 · Cited by 6
Nakao, S., Maezawa, M., Yamashita, M., Miyasaka, K., Hirofuji, S., Ichihara, N., Nokura, Y., Sugishita, K., Yamazaki, T., Tamaki, H., et al. (2025) · International Journal of Immunopathology and Pharmacology · doi:10.1177/03946320251327618 · Cited by 5
“26–28 The US package insert for Revlimid ® mentions increased mortality in chronic lymphocytic leukemia and mantle cell lymphoma in addition to fatal liver failure and fatal tumor lysis syndrome in the WARNINGS AND PRECAUTIONS section.”
Delforge, M., Michiels, A., Doyen, C., Kentos, A., Droogenbroeck, J. V., Offner, F. C., Bries, G., Demuynck, H., Vekemans, M. C., Meuleman, N., et al. (2011) · PubMed · doi:10.2143/acb.66.5.2062589 · Cited by 6
“Based on two prospective, randomised, phase III clinical trials (MM-009 and MM-010) (5, 6) the combination of lenalidomide plus dexamethasone is currently licensed for the treatment of MM patients, having received at least one prior line of treatment.”
BackgroundMethodResultInfluentialRamasamy, K., Mahmood, S., Lim, Z., Corderoy, S., Devereux, S., Mufti, G. J., Pagliuca, A., & Schey, S. (2011) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2011.03.004 · Cited by 5
Immunomodulatory agents in oncology
Zimmerman, T. M. (2009) · Update on Cancer Therapeutics · doi:10.1016/j.uct.2009.03.003 · Cited by 5
Current Phase II investigational proteasome inhibitors for the treatment of multiple myeloma
Bringhen, S., Gay, F., Donato, F., Troia, R., Mina, R., & Palumbo, A. P. (2014) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2014.920821 · Cited by 5
“The current standards of care for elderly patients include novel agents combined with melphalan-prednisone (MP) [7-9].”
BackgroundBlix, E. S., Kildal, A. B., Bertelsen, E. L., Waage, A., Myklebust, J. H., Kolstad, A., & Husebekk, A. (2015) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2014.12.027 · Cited by 5
“[37] Dimopoulos M, Spencer A, Attal M, Prince HM, Harousseau JL, Dmoszynska A, et al.”
BackgroundSequential or combination therapy for multiple myeloma
Nooka, A. K., & Lonial, S. (2012) · Expert Review of Hematology · doi:10.1586/ehm.12.49 · Cited by 7
Mondello, P., Pitini, V. V., Barresi, V., Brea, E. J., Mirto, C. D., Arrigo, C., Cuzzocrea, S., & Mian, M. (2015) · Experimental Hematology and Oncology · doi:10.1186/s40164-015-0030-1 · Cited by 6
“Nevertheless, lenalidomide represents the cornerstone of MM management, providing rapid and sustained disease control in relapsed/refractory [20, 21] as well as in newly diagnosed patients [22].”
BackgroundNovel combination approaches for myeloma
Lonial, S., & Nooka, A. K. (2015) · Hematology · doi:10.1182/asheducation-2015.1.286 · Cited by 5
Salvage therapies in relapsed and/or refractory myeloma: what is current and what is the future?
Thumallapally, N., Yu, H., Asti, D., Vennepureddy, A., & Terjanian, T. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s110189 · Cited by 5
Targeting the Bone Marrow Niche in Hematological Malignancies
Verma, D., & Krause, D. S. (2017) · Advances in stem cells and their niches · doi:10.1016/bs.asn.2016.12.004 · Cited by 5
Takemori, N., Imai, G., Hoshino, K., Ooi, A., & Kojima, M. (2018) · Journal of Medical Case Reports · doi:10.1186/s13256-017-1550-6 · Cited by 5
“Len has generally been used in combination with Dex for treating refractory and relapsed MM [1], newly diagnosed MM [2, 3], and transplant-ineligible MM [4].”
BackgroundAlahmadi, M. D., Masih‐Khan, E., Atenafu, E. G., Chen, C. I., Kukreti, V., Tiedemann, R. E., Trudel, S., & Reece, D. E. (2018) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2018.12.007 · Cited by 5
(KMMWP), T. K. M. M. W. P., Jo, J., Lee, H. S., Kım, K., Lee, J., Yoon, S., Bang, S., Kim, J. S., Eom, H., Yoon, D. H., et al. (2019) · Annals of Hematology · doi:10.1007/s00277-019-03904-7 · Cited by 5
Evolution or revolution in multiple myeloma therapy and the role of the UK
Cook, G., & Morris, C. T. C. M. (2020) · British Journal of Haematology · doi:10.1111/bjh.17148 · Cited by 7
“Lenalidomide, the first of the second-generation IMiDs, demonstrated significant efficacy, especially with dexamethasone, without the quality of life-limiting side effects of thalidomide and became established as treatment for RRMM and subsequently a front-line therapy for ASCT-ineligible patients.(29,43,44) As well a…”
BackgroundVirdis, P., Migheli, R., Bordoni, V., Fiorentino, F. P., Sanna, L., Marchesi, I., Pintore, G., Galleri, G., Muroni, M. R., Bagella, L., et al. (2021) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2021.5046 · Cited by 5
Potential mechanisms of resistance to current anti-thrombotic strategies in Multiple Myeloma
Comerford, C., Glavey, S. V., O’Sullivan, J. M., & Quinn, J. (2022) · Cancer Drug Resistance · doi:10.20517/cdr.2021.115 · Cited by 5
Silent venous thromboembolism in multiple myeloma patients treated with lenalidomide
Isoda, A., Sato, N., Miyazawa, Y., Matsumoto, Y., Koumoto, M., Ookawa, M., Sawamura, M., & Matsumoto, M. (2015) · International Journal of Hematology · doi:10.1007/s12185-015-1838-5 · Cited by 5
“However, when lenalidomide was combined with dexamethasone or cyclophosphamide without any thromboprophylaxis, the incidence of VTE increased significantly to 11–15 % [7, 8] and 14 % [9], respectively.”
BackgroundPrognostic indicators of lenalidomide for multiple myeloma: consensus and controversy
Kuroda, J., Kobayashi, T., & Taniwaki, M. (2015) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.2015.1044249 · Cited by 5
“conventional genotoxic agents and corticosteroids [16,17].”
Achieving an Early Myeloma Response in Patients With Kidney Impairment
Stringer, S. J., Cook, M. A., & Cockwell, P. (2012) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2012.07.005 · Cited by 5
Bergantim, R., Trigo, F., & Guimarães, J. E. (2012) · Experimental Hematology and Oncology · doi:10.1186/2162-3619-1-35 · Cited by 5
“Despite the improvement in treatment methodology over the 20 years that followed the introduction of ASCT, we witnessed on the early 2000’s another breakthrough when the first results on the use of the entitled new drugs - thalidomide [16-19] bortezomib and lenalidomide [20,21] – in induction therapy for MM were publi…”
Néphrotoxicité du lénalidomide
Fekih, R. E., & Izzedine, H. (2016) · Bulletin du Cancer · doi:10.1016/j.bulcan.2016.01.020 · Cited by 5
Sankowski, R., Herring, A., Keyvani, K., Frenzel, K., Wu, J., Röskam, S., Noelker, C., Bacher, M., & Al‐Abed, Y. (2016) · Molecular Medicine · doi:10.2119/molmed.2016.00163 · Cited by 6
Saxena, J., Saroj, S., Shah, P. V., & Rajput, S. (2019) · Indian Journal of Pharmaceutical Education and Research · doi:10.5530/ijper.53.1.18 · Cited by 5
Luzzio, F. A. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-815675-9.00010-2 · Cited by 8
Metadata
- Authors
- Dimopoulos, M., Spencer, A., Attal, M., Prince, H. M., Harousseau, J.-L., Dmoszynska, A., Miguel, J. S., Hellmann, A., Facon, T., Foà, R., Corso, A., Masliak, Z., Olesnyckyj, M., Yu, Z., Patin, J., Zeldis, J. B., & Knight, R. D.
- Affiliations
- National and Kapodistrian University of Athens (GR)
- The Alfred Hospital (AU)
- Hôpital Purpan (FR)
- Peter MacCallum Cancer Centre (AU)
- Centre Hospitalier Universitaire de Nantes (FR)
- Gdańsk Medical University (PL)
- Hôpital Claude Huriez (FR)
- Sapienza University of Rome (IT)
- Policlinico San Matteo Fondazione (IT)
- Institute of Blood Pathology and Transfusion Medicine of the National Academy of Medical Sciences of Ukraine (UA)
- Celgene (United States) (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2007-11-22
- Volume
- 357
- Issue
- 21
- Pages
- 2123-2132
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1992538067
- Semantic Scholar
- 32cf6aa2c629905ca550153f79309e6594cf499b
- Cited by
- 1,450
- References
- 17
- Citations by year
- 2026: 8 · 2025: 14 · 2024: 24 · 2023: 55 · 2022: 50 · 2021: 46 · 2020: 59 · 2019: 54 · 2018: 68 · 2017: 87 · 2016: 97 · 2015: 86 · 2014: 90 · 2013: 135 · 2012: 126
- FWCI
- 67.07
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Keywords
- lenalidomide, dexamethasone, relapsed/refractory multiple myeloma, thalidomide analogues, time to progression, overall survival, complete response, neutropenia, venous thromboembolism, thrombocytopenia, combination chemotherapy, adverse events, immunomodulators, corticosteroids, treatment efficacy comparison
- MeSH terms
- Lenalidomide, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Dexamethasone, Drug Therapy, Combination, Female, Glucocorticoids, Humans, Immunologic Factors, Male, Middle Aged, Multiple Myeloma, Recurrence, Thalidomide, Survival Analysis, Disease Progression
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.